PE20150723A1 - Compuestos antiviricos para el vsr - Google Patents
Compuestos antiviricos para el vsrInfo
- Publication number
- PE20150723A1 PE20150723A1 PE2015000497A PE2015000497A PE20150723A1 PE 20150723 A1 PE20150723 A1 PE 20150723A1 PE 2015000497 A PE2015000497 A PE 2015000497A PE 2015000497 A PE2015000497 A PE 2015000497A PE 20150723 A1 PE20150723 A1 PE 20150723A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- rsv
- methylpropanoyl
- indol
- chloro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- -1 (5-chloro-1- (3- (methylsulfonyl) propyl) -1H-indol-2-yl) -methyl-1- (2-hydroxy-2- methylpropanoyl) spiro [piperidin-4,3'pyrrolo [2,3-c] pyridin] -2 '(1'H) -one Chemical compound 0.000 abstract 1
- HPXABIJFZRVCAL-UHFFFAOYSA-N 4-[5-chloro-2-[[1-(2-hydroxy-2-methylpropanoyl)-2'-oxospiro[azetidine-3,3'-indole]-1'-yl]methyl]indol-1-yl]butanenitrile Chemical compound C1N(C(=O)C(C)(O)C)CC21C1=CC=CC=C1N(CC=1N(C3=CC=C(Cl)C=C3C=1)CCCC#N)C2=O HPXABIJFZRVCAL-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Referida a inhibidores de la replicacion del virus sincitial respiratorio (VSR) de formula (RI) incluyendo sus formas estereoquimicamente isomericas y sus sales o solvatos, donde R22, W, Q, V, Z, p, s y Het tienen el significado que se define en la presente solicitud. Tambien esta referida a procesos para preparar dichos compuestos, a composiciones farmaceuticas que los contienen. Son compuestos preferidos: 4-(5-cloro-2-((1-(2-hidroxi-2-metilpropanoil)-2'-oxoespiro[azetidin-3,3'-indolin]-1'-il)metil)-1H-indol-1-il)butanonitrilo, 1'-((5-cloro-1-(3-(metilsulfonil)propil)-1H-indol-2-il)-metil-1-(2-hidroxi-2-metilpropanoil)espiro[piperidin-4,3'pirrolo[2,3-c]piridin]-2'(1'H)-ona, entre otros
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188694 | 2012-10-16 | ||
| EP13159431 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150723A1 true PE20150723A1 (es) | 2015-05-15 |
Family
ID=49385250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000497A PE20150723A1 (es) | 2012-10-16 | 2013-10-15 | Compuestos antiviricos para el vsr |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9617289B2 (es) |
| EP (1) | EP2909195B1 (es) |
| JP (1) | JP6375300B2 (es) |
| KR (1) | KR102280918B1 (es) |
| CN (1) | CN104903313B (es) |
| AR (1) | AR093020A1 (es) |
| AU (1) | AU2013334001B2 (es) |
| BR (1) | BR112015008325B1 (es) |
| CA (1) | CA2884491C (es) |
| CL (1) | CL2015000925A1 (es) |
| CY (1) | CY1119566T1 (es) |
| DK (1) | DK2909195T3 (es) |
| EA (1) | EA026628B1 (es) |
| EC (1) | ECSP15014941A (es) |
| ES (1) | ES2640446T3 (es) |
| HR (1) | HRP20171351T1 (es) |
| HU (1) | HUE033476T2 (es) |
| IL (1) | IL237857A (es) |
| LT (1) | LT2909195T (es) |
| ME (1) | ME02835B (es) |
| MX (1) | MX363717B (es) |
| MY (1) | MY172021A (es) |
| NZ (1) | NZ705759A (es) |
| PE (1) | PE20150723A1 (es) |
| PH (1) | PH12015500780B1 (es) |
| PL (1) | PL2909195T3 (es) |
| PT (1) | PT2909195T (es) |
| SA (1) | SA515360258B1 (es) |
| SG (1) | SG11201503025WA (es) |
| SI (1) | SI2909195T1 (es) |
| TW (1) | TWI598351B (es) |
| UA (1) | UA114531C2 (es) |
| WO (1) | WO2014060411A1 (es) |
| ZA (1) | ZA201502532B (es) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI501967B (zh) * | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| CN104583218B (zh) | 2012-04-26 | 2018-04-24 | 百时美施贵宝公司 | 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物 |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| SI2864323T1 (sl) | 2012-06-15 | 2017-08-31 | Janssen Sciences Ireland Uc | Derivati 1,3-dihidro-2h-benzimidazol-2-ona substituirani s heterocikli, kot protivirusna zdravila respiratornega sincicijskega virusa |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| TW201932456A (zh) | 2013-01-15 | 2019-08-16 | 美商英塞特控股公司 | 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| BR112015028475A2 (pt) * | 2013-05-14 | 2017-07-25 | Hoffmann La Roche | novos aza-oxo-indois para o tratamento ou profilaxia de infecção virótica respiratória sincitial |
| CN105392787B (zh) * | 2013-05-14 | 2017-11-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚 |
| MX2016001855A (es) * | 2013-08-12 | 2016-05-24 | Hoffmann La Roche | Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio. |
| WO2015022301A1 (en) * | 2013-08-15 | 2015-02-19 | F. Hoffmann-La Roche Ag | Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
| MX2016002367A (es) | 2013-08-23 | 2016-10-28 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. |
| PT3081569T (pt) | 2013-12-10 | 2019-12-30 | Shandong Danhong Pharmaceutical Co Ltd | Derivado de imidazole utilizado como agente antiviral e sua utilização na preparação do medicamento |
| TWI671299B (zh) * | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為ｒｓｖ抗病毒化合物之螺脲化合物 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| GB201417707D0 (en) | 2014-10-07 | 2014-11-19 | Viral Ltd | Pharmaceutical compounds |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| ES2821649T3 (es) | 2015-06-08 | 2021-04-27 | Shangdong Danhong Pharmaceutical Co Ltd | Método para preparar derivados de imidazol e intermedios de los mismos y formas cristalinas |
| RS63653B1 (sr) | 2015-07-22 | 2022-11-30 | Enanta Pharm Inc | Benzodiazepinski derivati kao inhibitori rsv |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| KR20180087290A (ko) | 2015-11-27 | 2018-08-01 | 얀센 사이언시즈 아일랜드 유씨 | 인플루엔자 바이러스 감염에서 사용하기 위한 복소환식 인돌 |
| WO2017123884A1 (en) | 2016-01-15 | 2017-07-20 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| MX381314B (es) * | 2016-01-20 | 2025-03-12 | Janssen Sciences Ireland Uc | Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza |
| EP3414247B1 (en) * | 2016-02-08 | 2021-04-21 | F. Hoffmann-La Roche AG | Spiroindolinones as ddr1 inhibitors |
| HRP20210900T1 (hr) | 2016-08-04 | 2021-08-20 | ReViral Limited | Derivati pirimidina i njihova upotreba u liječenju ili prevenciji infekcije respiratornog sincicijalnog virusa |
| WO2018038667A1 (en) * | 2016-08-25 | 2018-03-01 | Medivir Ab | Respiratory syncytial virus inhibitors |
| WO2018038668A1 (en) * | 2016-08-25 | 2018-03-01 | Medivir Ab | Respiratory syncytial virus inhibitors |
| WO2018152413A1 (en) | 2017-02-16 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| GB201711704D0 (en) | 2017-07-20 | 2017-09-06 | Reviral Ltd | Pharmaceutical compounds |
| CN107383011B (zh) * | 2017-08-01 | 2019-05-10 | 深圳百奥捷生物科技有限公司 | 一种分离自连翘叶黄芩的抗病毒生物碱及其制备方法 |
| CN107253951B (zh) * | 2017-08-01 | 2019-05-10 | 深圳百奥捷生物科技有限公司 | 一种嘌呤生物碱及其作为抗rsv病毒药物的应用 |
| CN109369658B (zh) * | 2017-08-08 | 2020-01-31 | 沈阳药科大学 | 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法 |
| WO2019067864A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV |
| CN111343990B (zh) | 2017-11-13 | 2023-08-04 | 英安塔制药有限公司 | 苯并二氮杂䓬-2-酮和苯并氮杂䓬-2-酮衍生物的拆分方法 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN113194983B (zh) | 2018-09-06 | 2025-11-18 | 奇达拉治疗公司 | 用于治疗病毒感染的组合物及方法 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| UY38614A (es) | 2019-03-18 | 2020-10-30 | Enanta Pharm Inc | Derivados de benzodiazepinas como inhibidores del rsv |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| EP3982994A4 (en) * | 2019-06-13 | 2023-10-04 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of respiratory syncytial virus |
| BR112022002698A2 (pt) | 2019-08-14 | 2022-07-19 | Incyte Corp | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 |
| TWI861205B (zh) | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| EP4028392A1 (en) * | 2019-09-09 | 2022-07-20 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of respiratory syncytial virus |
| MX2022003984A (es) | 2019-10-04 | 2022-07-27 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| BR112022006977A2 (pt) | 2019-10-11 | 2022-09-20 | Incyte Corp | Aminas bicíclicas como inibidores de cdk2 |
| KR20220091465A (ko) * | 2019-10-30 | 2022-06-30 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 3-(｛5-클로로-1-[3-(메틸설포닐)프로필]-1H-인돌-2-일｝메틸)-1-(2,2,2-트리플루오로에틸)-1,3-디히드로-2H-이미다조[4,5-c]피리딘-2-온의 합성 |
| WO2021098732A1 (zh) * | 2019-11-18 | 2021-05-27 | 江苏恩华药业股份有限公司 | 一种1',2'-二氢-3'h-螺[环丁烷1,4'-异喹啉]-3'-酮衍生物及其应用 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| JP2023528969A (ja) | 2020-06-11 | 2023-07-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ３－（｛５－クロロ－１－［３－（メチルスルホニル）プロピル］－１Ｈ－インドール－２ イル｝メチル）－１－（２，２，２－トリフルオロエチル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－オンのヘミ（Ｌ）－酒石酸塩形態及びそれを含む医薬組成物 |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| KR20230161976A (ko) | 2021-02-26 | 2023-11-28 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스성 헤테로사이클릭 화합물 |
| WO2022184606A1 (en) * | 2021-03-01 | 2022-09-09 | Janssen Sciences Ireland Unlimited Company | Synthesis of rilematovir |
| CN115650902A (zh) * | 2021-05-12 | 2023-01-31 | 苏州恩华生物医药科技有限公司 | 1′,2′-二氢-3′h-螺[环丁烷1,4′-异喹啉]-3′-酮衍生物的盐及其应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023109926A1 (zh) * | 2021-12-17 | 2023-06-22 | 南京药石科技股份有限公司 | 螺环氧化吲哚类化合物及其用于制备抗病毒蛋白酶抑制剂药物的用途 |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023200441A1 (en) * | 2022-04-13 | 2023-10-19 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| CN118908932A (zh) * | 2024-07-18 | 2024-11-08 | 湖北固润科技股份有限公司 | 1,4-氧硫鎓盐及其制备方法和产酸剂型阳离子光引发剂的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489338B2 (en) * | 2000-06-13 | 2002-12-03 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrimidine antiviral agents |
| US6506738B1 (en) * | 2000-09-27 | 2003-01-14 | Bristol-Myers Squibb Company | Benzimidazolone antiviral agents |
| PE20050068A1 (es) | 2003-02-06 | 2005-03-11 | Novartis Ag | 2-cianopirrolopirimidinas como inhibidores de la catepsina s |
| GB0304640D0 (en) | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI541241B (zh) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
| TWI530495B (zh) * | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
| TWI527814B (zh) * | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| GB201119538D0 (en) * | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
-
2013
- 2013-10-15 LT LTEP13779195.0T patent/LT2909195T/lt unknown
- 2013-10-15 CA CA2884491A patent/CA2884491C/en active Active
- 2013-10-15 EP EP13779195.0A patent/EP2909195B1/en active Active
- 2013-10-15 AU AU2013334001A patent/AU2013334001B2/en not_active Ceased
- 2013-10-15 PE PE2015000497A patent/PE20150723A1/es active IP Right Grant
- 2013-10-15 SG SG11201503025WA patent/SG11201503025WA/en unknown
- 2013-10-15 AR ARP130103738A patent/AR093020A1/es active IP Right Grant
- 2013-10-15 PL PL13779195T patent/PL2909195T3/pl unknown
- 2013-10-15 US US14/435,604 patent/US9617289B2/en not_active Expired - Fee Related
- 2013-10-15 MY MYPI2015000995A patent/MY172021A/en unknown
- 2013-10-15 BR BR112015008325-0A patent/BR112015008325B1/pt not_active IP Right Cessation
- 2013-10-15 ES ES13779195.0T patent/ES2640446T3/es active Active
- 2013-10-15 NZ NZ705759A patent/NZ705759A/en not_active IP Right Cessation
- 2013-10-15 HU HUE13779195A patent/HUE033476T2/en unknown
- 2013-10-15 KR KR1020157009775A patent/KR102280918B1/ko not_active Expired - Fee Related
- 2013-10-15 EA EA201590748A patent/EA026628B1/ru not_active IP Right Cessation
- 2013-10-15 HR HRP20171351TT patent/HRP20171351T1/hr unknown
- 2013-10-15 JP JP2015537225A patent/JP6375300B2/ja not_active Expired - Fee Related
- 2013-10-15 UA UAA201504703A patent/UA114531C2/uk unknown
- 2013-10-15 MX MX2015004787A patent/MX363717B/es unknown
- 2013-10-15 CN CN201380053657.8A patent/CN104903313B/zh not_active Expired - Fee Related
- 2013-10-15 DK DK13779195.0T patent/DK2909195T3/en active
- 2013-10-15 WO PCT/EP2013/071525 patent/WO2014060411A1/en not_active Ceased
- 2013-10-15 ME MEP-2017-210A patent/ME02835B/me unknown
- 2013-10-15 SI SI201330771T patent/SI2909195T1/sl unknown
- 2013-10-15 TW TW102137059A patent/TWI598351B/zh not_active IP Right Cessation
- 2013-10-15 PT PT137791950T patent/PT2909195T/pt unknown
-
2015
- 2015-03-22 IL IL237857A patent/IL237857A/en active IP Right Grant
- 2015-04-08 PH PH12015500780A patent/PH12015500780B1/en unknown
- 2015-04-09 SA SA515360258A patent/SA515360258B1/ar unknown
- 2015-04-13 CL CL2015000925A patent/CL2015000925A1/es unknown
- 2015-04-15 EC ECIEPI201514941A patent/ECSP15014941A/es unknown
- 2015-04-15 ZA ZA2015/02532A patent/ZA201502532B/en unknown
-
2017
- 2017-09-13 CY CY20171100965T patent/CY1119566T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150723A1 (es) | Compuestos antiviricos para el vsr | |
| DK3359542T3 (da) | Spiro[3h-indol-3,2'-pyrrolidin]-2(1h)-on-forbindelser og derivater som mdm2-p53-inhibitorer | |
| MX345830B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
| SV2010003642A (es) | Compuestos | |
| HUE046057T2 (hu) | Új spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és származékok, mint MDM2-P53-inhibitorok | |
| ECSP10010585A (es) | Compuestos de 2- imido- 3- metil pirrolo pirimidinona fenilo- sustituidos como inhibidores bace- 1, composiciones, y su uso | |
| PE20150758A1 (es) | Nuevos derivados biciclicos | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| UA122868C2 (uk) | Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| MX388533B (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CL2013001723A1 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina; metodos de preparacion; composicion farmaceutica; y el uso en el tratamiento de los trastornos mediados por la cinasa de linfoma anaplasico. | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| PE20151413A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| UY29177A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos | |
| MX2017013219A (es) | Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. | |
| PH12015501955A1 (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| PE20151755A1 (es) | Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos | |
| MX376113B (es) | Derivados de azabenzimidazoles como moduladores del receptor ampa, y el uso de los mismos en el tratamiento de enfermedades asociadas con los receptores ampa. | |
| UY39887A (es) | (r)-(2-cloro-3-(trifluorometil)fenil)(1-(5-fluoropirimidin2-il)-4-metil-6,7-dihidro-1h-[1,2,3]triazolo-[4,5-c]piridin5(4h)-il)metanona como modulador del receptor p2x7 | |
| CL2009001884A1 (es) | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| CL2011002467A1 (es) | Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional. | |
| ECSP10010429A (es) | Derivados bicíclicos heterocíclicos o espirobicíclicos heterocíclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparación y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |